Document is current
Any future updates will be listed below
-
Authors
Katsuya, Yuki
Takenaka, Satoshi
Takahashi, Shunji
Yamamoto, Noboru
- License Information
-
More Information
Article History
Received: 22 September 2025
Accepted: 29 November 2025
First Online: 22 January 2026
Declarations
:
: N Yamamoto has received research grants as principal investigator (in institutional capacity) from Astellas Pharma, Chugai, Eisai, Taiho Pharmaceutical, Bristol-Myers Squibb, Pfizer, Novartis, Eli Lilly, AbbVie, Daiichi-Sankyo, Bayer, Boehringer Ingelheim, Kyowa Kirin, Takeda, Ono Pharmaceutical, Janssen Pharma, MSD, MERCK, GSK, Chiome Bioscience, Otsuka Pharmaceutical, Carna Biosciences, Genmab, Shionogi, TORAY, KAKEN, AstraZeneca, InventisBio, Rakuten Medical, Amgen, Bicycle Therapeutics, and Zymeworks. N Yamamoto has received consulting fees (in personal capacity) from Eisai, Boehringer Ingelheim, Cmic, Chugai, MERCK, Healios, Mitsubishi Tanabe, Rakuten Medical, IQVIA, Noile-Immune Biotech, and Janssen Pharma. N Yamamoto has received payments for lectures (in personal capacity) from Chugai, Daiichi-Sankyo, and Eisai. Y Katsuya has received support for traveling to meetings not for the current study, but for another study from Ono Pharmaceutical. S Takenaka and S Takahashi declare that they have no conflicts of interest.
